National Institute for Health Research Health Protection Research Unit in Modelling Methodology and Medical Research Council Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, UK.
National Institute for Health Research Health Protection Research Unit in Modelling Methodology and Medical Research Council Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, UK; Modelling and Economics Unit, National Infection Service, Public Health England, London, UK.
Lancet Public Health. 2018 Jun;3(6):e271-e278. doi: 10.1016/S2468-2667(18)30071-9.
Chlamydia screening programmes have been implemented in several countries, but the effects of screening on incidence, prevalence, and reproductive sequelae remain unclear. In England, despite increases in testing with the rollout of the National Chlamydia Screening Programme (NCSP; 2003-08), prevalence estimated in 10-yearly population-based surveys was similar before (1999-2001) and after (2010-12) the programme. However, the precision of these previous estimates was limited by the low numbers of infections. We aimed to establish annual, rather than 10-yearly, estimates of chlamydia prevalence and infection duration.
In this model-based analysis, we used previously published minimum and maximum estimates and Public Health England data for chlamydia test coverage and diagnoses in men and women aged 15-24 years in England, before, during, and after the scale-up of national chlamydia screening. We used a mechanistic model, which accounted for symptomatic chlamydia testing and asymptomatic screening, to estimate changes in prevalence and average duration of infections for each year. We describe estimates derived from the maximum and minimum numbers of tests and diagnoses as maximum and minimum estimates, regardless of their relative magnitude.
The data included numbers of tests and diagnoses in men and women aged 15-19 years and 20-24 years in England each year from 2000 to 2015. We estimated reductions in prevalence and average infection duration in both sexes once screening was fully implemented. From 2008 to 2010, estimated posterior median prevalence reductions in people aged 15-24 years were 0·68 percentage points (95% credible interval 0·26-1·40; minimum) and 0·66 percentage points (0·25-1·37; maximum) for men and 0·77 percentage points (0·45-1·27) for women (minimum and maximum estimates were the same for women). Over the same time period, mean duration of infection reduced by 75 days (95% credible interval 17-255; minimum) and 74 days (95% credible interval 17-247; maximum) in men and 30 days (22-40) in women. Since 2010, some of the progress made by the NCSP has been reversed, alongside a reduction in testing.
Our analysis provides the first evidence for a reduction in chlamydia prevalence in England concurrent with large-scale population testing. It also shows a consistent decline in the average duration of infections, which is a measure of screening effectiveness that is unaffected by behavioural changes.
National Institute for Health Research, Medical Research Council.
已有多个国家实施了衣原体筛查项目,但筛查对发病率、流行率和生殖后遗症的影响仍不清楚。在英国,尽管随着国家衣原体筛查项目(NCSP;2003-08 年)的推出,检测量有所增加,但在该项目实施之前(1999-2001 年)和之后(2010-12 年)的十年期基于人群的调查中估计的流行率相似。然而,这些先前估计的准确性受到感染数量低的限制。我们的目的是建立年度而非十年的衣原体流行率和感染持续时间估计值。
在这项基于模型的分析中,我们使用了之前发表的最小和最大估计值以及英国公共卫生署的数据,这些数据涵盖了英格兰 15-24 岁男性和女性的衣原体检测覆盖率和诊断率,涵盖了国家衣原体筛查扩大之前、期间和之后的情况。我们使用一种机制模型,该模型考虑了有症状的衣原体检测和无症状的筛查,以估计每年的流行率和感染平均持续时间的变化。我们将最大和最小测试和诊断数量得出的估计值描述为最大和最小估计值,而不考虑其相对大小。
该数据包括 2000 年至 2015 年期间英格兰 15-19 岁和 20-24 岁男性和女性每年的检测和诊断数量。我们估计一旦全面实施筛查,两性的流行率和平均感染持续时间都会降低。从 2008 年到 2010 年,估计 15-24 岁人群的后验中位数流行率降低,男性分别为 0.68 个百分点(95%置信区间 0.26-1.40;最小值)和 0.66 个百分点(0.25-1.37;最大值),女性为 0.77 个百分点(0.45-1.27)(女性的最小和最大估计值相同)。在同一时期,男性感染持续时间平均减少 75 天(95%置信区间 17-255;最小值)和 74 天(95%置信区间 17-247;最大值),女性减少 30 天(22-40)。自 2010 年以来,NCSP 的部分进展已经逆转,同时检测量也有所减少。
我们的分析首次提供了与大规模人群检测同时发生的英格兰衣原体流行率降低的证据。它还显示了感染平均持续时间的持续下降,这是衡量筛查效果的一个指标,不受行为变化的影响。
英国国家卫生研究院,医学研究理事会。